| 000 | 01030 a2200289 4500 | ||
|---|---|---|---|
| 005 | 20250514070323.0 | ||
| 264 | 0 | _c20030708 | |
| 008 | 200307s 0 0 eng d | ||
| 022 | _a0887-6924 | ||
| 024 | 7 |
_a10.1038/sj.leu.2402954 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCarella, A M | |
| 245 | 0 | 0 |
_aQuestioning the aim of CML therapy in the era of Imatinib? _h[electronic resource] |
| 260 |
_bLeukemia _cJun 2003 |
||
| 300 |
_a1199-200 p. _bdigital |
||
| 500 | _aPublication Type: Letter; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
| 650 | 0 | 4 | _aBenzamides |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImatinib Mesylate |
| 650 | 0 | 4 |
_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _xdrug therapy |
| 650 | 0 | 4 | _aNeoplasm, Residual |
| 650 | 0 | 4 |
_aPiperazines _xtherapeutic use |
| 650 | 0 | 4 |
_aPyrimidines _xtherapeutic use |
| 773 | 0 |
_tLeukemia _gvol. 17 _gno. 6 _gp. 1199-200 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/sj.leu.2402954 _zAvailable from publisher's website |
| 999 |
_c12550976 _d12550976 |
||